Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists.
Enantiomeric propanolamines have been identified as a new class of NR2B-selective NMDA receptor antagonists. The most effective agents are biaryl structures, synthesized in six steps with overall yields ranging from 11-64%. The compounds are potent and selective inhibitors of NR2B-containing recombinant NMDA receptors with IC 50 values between 30-100 nM. Potency is strongly controlled by substitution on both rings and the centrally located amine nitrogen. SAR analysis suggests that well-balanced polarity and chain-length factors provide the greatest inhibitory potency. Structural comparisons based on 3D shape analysis and electrostatic complementarity support this conclusion. The antagonists are neuroprotective in both in vitro and in vivo models of ischemic cell death. In addition, some compounds exhibit anticonvulsant properties. Unlike earlier generation NMDA receptor antagonists and some NR2B-selective antagonists, the present series of propanolamines does not cause increased locomotion in rodents. Thus, the NR2B-selective antagonists exhibit a range of therapeutically interesting properties.
Tahirovic
Yesim A
YA
Department of Chemistry, Emory University, Atlanta, Georgia, USA.
Geballe
Matthew
M
Gruszecka-Kowalik
Ewa
E
Myers
Scott J
SJ
Lyuboslavsky
Polina
P
Le
Phuong
P
French
Adam
A
Irier
Hasan
H
Choi
Woo-Baeg
WB
Easterling
Keith
K
Yuan
Hongjie
H
Wilson
Lawrence J
LJ
Kotloski
Robert
R
McNamara
James O
JO
Dingledine
Raymond
R
Liotta
Dennis C
DC
Traynelis
Stephen F
SF
Snyder
James P
JP
D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology; D001812:Blood-Brain Barrier; D001921:Brain / Q000378:metabolism; D018691:Excitatory Amino Acid Antagonists / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D009682:Magnetic Resonance Spectroscopy; D013058:Mass Spectrometry; D009043:Motor Activity / Q000187:drug effects; D011412:Propanolamines / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D051381:Rats; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D014981:Xenopus
D000927:Anticonvulsants; D018691:Excitatory Amino Acid Antagonists; C121001:NR2B NMDA receptor; D011412:Propanolamines; D016194:Receptors, N-Methyl-D-Aspartate
J Physiol. 1996 Dec 15;497 ( Pt 3):761-72
9003561
Eur J Pharmacol. 1979 May 1;55(3):323-6
37098
Eur J Pharmacol. 1989 Aug 3;166(3):359-66
2553433
Pharmacotherapy. 1996 Jan-Feb;16(1):82-93
8700797
Pharmacol Rev. 1999 Mar;51(1):7-61
10049997
Nature. 2000 Feb 10;403(6770):614-5
10688187
J Neurochem. 1998 May;70(5):2120-8
9572299
Ann Neurol. 1988 Oct;24(4):543-51
2853604
J Neurosurg. 1997 Dec;87(6):921-6
9384405
Neuron. 1999 May;23(1):171-80
10402203
Crit Care Med. 1997 Jun;25(6):1037-43
9201058
Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):13019-24
14559973
Science. 2004 Mar 19;303(5665):1813-8
15031495
J Comput Aided Mol Des. 2005 Sep-Oct;19(9-10):661-86
16328855
J Neurosci. 1998 Aug 15;18(16):6163-75
9698310
Curr Drug Targets CNS Neurol Disord. 2005 Apr;4(2):143-51
15857299
Brain Res Brain Res Rev. 1995 Feb;20(2):250-67
7795658
Trends Neurosci. 1999 Sep;22(9):391-7
10441299
J Neurosci. 2002 Jul 15;22(14):5955-65
12122058
J Med Chem. 2007 Jan 11;50(1):74-82
17201411
Nat Neurosci. 1998 Dec;1(8):659-67
10196581
Exp Neurol. 2004 May;187(1):86-93
15081591
Mol Pharmacol. 1999 Jun;55(6):957-69
10347236
J Pharmacol Exp Ther. 1999 Sep;290(3):1393-408
10454519
Curr Med Chem. 2004 Feb;11(3):389-96
14965239
J Pharmacol Exp Ther. 2002 Sep;302(3):940-8
12183650
Psychopharmacology (Berl). 2005 Apr;179(1):4-29
15731895
Curr Pharm Des. 1999 May;5(5):381-404
10213801
Nature. 1991 Nov 7;354(6348):31-7
1834949
J Neurosci. 1987 Feb;7(2):357-68
2880937
Neuron. 1994 Mar;12(3):529-40
7512349
J Med Chem. 1995 Aug 4;38(16):3138-45
7636876
J Neurosci. 2005 Jan 12;25(2):308-17
15647474
J Med Chem. 1999 Aug 26;42(17):3412-20
10464027
Bioorg Med Chem Lett. 2003 Feb 24;13(4):693-6
12639560
Eur J Pharmacol. 1989 Aug 11;167(1):127-35
2550253
Psychopharmacology (Berl). 2004 Dec;177(1-2):61-7
15316716
Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):11062-7
10984504
Science. 1956 Jul 6;124(3210):29-31
13337345
Br J Pharmacol. 1992 Aug;106(4):958-65
1393293
Eur J Pharmacol. 2001 Oct 26;430(1):147-8
11698075
J Comput Aided Mol Des. 2004 Jul-Sep;18(7-9):451-74
15729846
Curr Med Chem. 2001 Sep;8(11):1275-89
11562266
Bioorg Med Chem Lett. 2004 Aug 2;14(15):3953-6
15225705
J Med Chem. 2004 Apr 8;47(8):2089-96
15056006
J Neurosci Methods. 1987 May;20(1):83-90
2884353
Neuron. 2000 Dec;28(3):911-25
11163276
Bioorg Med Chem Lett. 2003 Nov 3;13(21):3859-61
14552795
Mol Pharmacol. 1996 Dec;50(6):1541-50
8967976
Biochem Biophys Res Commun. 1992 Jun 30;185(3):826-32
1352681
Neuropharmacology. 1999 Feb;38(2):243-51
10218865
Mol Pharmacol. 1993 Oct;44(4):851-9
7901753
Chemistry. 2000 Jun 16;6(12):2200-4
10926226
J Neuropathol Exp Neurol. 1996 Jan;55(1):1-13
8558164
Science. 1992 May 22;256(5060):1217-21
1350383
J Med Chem. 2000 Jul 13;43(14):2609-45
10893301
Neuropharmacology. 1999 May;38(5):611-23
10340299
Prog Neurobiol. 1995 Dec;47(6):477-511
8787032
Chem Biol. 2005 Apr;12(4):427-37
15850979
Curr Top Med Chem. 2006;6(7):697-709
16719810
Protein Sci. 2005 Sep;14(9):2275-83
16131656
Br J Pharmacol. 1998 Feb;123(3):463-72
9504387
J Pharmacol Exp Ther. 1997 Dec;283(3):1285-92
9400004
Crit Rev Neurobiol. 2004;16(3):187-224
15701057